Journal article · 2020
How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations
Therapeutic Innovation & Regulatory Science, 54(3), 577–585 · Published 6 January 2020 · DOI 10.1007/s43441-019-00090-6
In brief
“How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations” is a 2020 journal article by Marianne Botoft Hansen and 2 co-authors, published in Therapeutic Innovation & Regulatory Science. OpenAlex counts 21 citations as of 22 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 21
- Most cited in
- 2022 (5)
- Field-weighted impact
- 2.39
- Authors
- 3
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Hansen, M. B., Nørgaard, L. S., & Hallgreen, C. E. (2020). How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations. Therapeutic Innovation & Regulatory Science, 54(3), 577–585. https://doi.org/10.1007/s43441-019-00090-6
MLA 9
Hansen, Marianne Botoft, et al. “How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations.” Therapeutic Innovation & Regulatory Science, vol. 54, no. 3, 2020, pp. 577–585. https://doi.org/10.1007/s43441-019-00090-6.
Chicago
Hansen, Marianne Botoft, Lotte Stig Nørgaard, and Christine E. Hallgreen. 2020. “How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations.” Therapeutic Innovation & Regulatory Science 54 (3): 577–585. https://doi.org/10.1007/s43441-019-00090-6.
Harvard
Hansen, M. B., Nørgaard, L. S. and Hallgreen, C. E. (2020) ‘How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations’, Therapeutic Innovation & Regulatory Science, 54(3), pp. 577–585. doi:10.1007/s43441-019-00090-6.
IEEE
M. B. Hansen, L. S. Nørgaard, and C. E. Hallgreen, “How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations,” Therapeutic Innovation & Regulatory Science, vol. 54, no. 3, pp. 577–585, 2020, doi: 10.1007/s43441-019-00090-6.
BibTeX
@article{hansen2020involve,
title = {{How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations}},
author = {Hansen, Marianne Botoft and Nørgaard, Lotte Stig and Hallgreen, Christine E.},
journal = {Therapeutic Innovation \& Regulatory Science},
year = {2020},
volume = {54},
number = {3},
pages = {577--585},
doi = {10.1007/s43441-019-00090-6},
url = {https://doi.org/10.1007/s43441-019-00090-6}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2020 | 2 | |
| 2021 | 4 | |
| 2022 | 5 | |
| 2023 | 2 | |
| 2024 | 3 | |
| 2025 | 1 | |
| 2026 | 4 |
Its field-weighted citation impact is 2.39: it has been cited 2.39 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Health Professions › General Health Professions › Mental Health and Patient Involvement
- patient involvement
- pharmaceutical industry
- regulatory agencies
- patient associations
- stakeholder perspectives
- barriers to patient involvement
- trust and transparency
- drug approval
Work with this paper
Most-cited papers in Health Professions
- DETERMINATION OF SERUM PROTEINS BY MEANS OF THE BIURET REACTIONAllan Godfrey Gornall, Charles J. Bardawill, Maxima M. David · Journal of Biological Chemistry · 1949 · 16,172 citations
- Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation scienceLaura J. Damschroder, David Clark Aron, Rosalind E. Keith and 3 more · Implementation Science · 2009 · 15,527 citations
- FUNCTIONAL EVALUATION: THE BARTHEL INDEX.FLORENCE I. MAHONEY, DOROTHEA W. BARTHEL · PubMed · 1965 · 15,488 citations
- The Timed “Up & Go”: A Test of Basic Functional Mobility for Frail Elderly PersonsDiane Podsiadlo, Sandra Richardson · Journal of the American Geriatrics Society · 1991 · 15,001 citations
- National Committee for Clinical Laboratory StandardsErika Bruck · PEDIATRICS · 1980 · 14,735 citations
Questions about this paper
How do I cite this paper in APA style?
Hansen, M. B., Nørgaard, L. S., & Hallgreen, C. E. (2020). How and Why to Involve Patients in Drug Development: Perspectives From the Pharmaceutical Industry, Regulatory Authorities, and Patient Organizations. Therapeutic Innovation & Regulatory Science, 54(3), 577–585. https://doi.org/10.1007/s43441-019-00090-6
How many times has this paper been cited?
21 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Marianne Botoft Hansen, Lotte Stig Nørgaard, Christine E. Hallgreen.
What is the DOI of this paper?
10.1007/s43441-019-00090-6, permanently at https://doi.org/10.1007/s43441-019-00090-6. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.